Giraudo Bryan 4

What Happened
Bryan Giraudo, the Chief Operating Officer and Chief Financial Officer of Gossamer Bio (GOSS), exchanged (disposed to the issuer) a series of existing derivative awards and, simultaneously, received matching repriced option awards on March 19, 2026. The filing shows 11 dispositions and 11 grants, each pair for the same share counts, totaling 2,960,751 underlying shares. The issuer reduced the per-share exercise price of the repriced options to $0.45. No cash purchase or open-market sale is reported — these are option cancellations and re-grants (derivative transactions), not stock sales.

Key Details

• Transaction date: March 19, 2026; Form 4 filed March 20, 2026.
• Total shares involved: 2,960,751 underlying shares (sum of listed dispositions and matching grants).
• New exercise price: $0.45 per share for the repriced options (per footnote).
• Consideration/price shown on the Form 4: N/A for the dispositions/grants (derivative transactions).
• Plan: Awards were under the Issuer’s 2019 Incentive Award Plan.
• Vesting/terms: Footnote states all other terms (including vesting and term) remain unchanged except for the reduced exercise price; grants vest per the original schedule and are subject to continued service.
• Shares owned after transaction: Not disclosed in the provided summary of this filing.
• Timeliness: Reported the next day (Form 4 filed 3/20 for 3/19 transactions); no late filing indicated.

Context
This was a company-approved one-time option repricing (not an open-market buy or sale). For retail investors, note this transaction reflects a modification of option economics (lower exercise price) rather than an insider buying or selling stock in the market. It does not by itself indicate insider sentiment about the company’s shares; vesting remains subject to continued service.